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Original Studies 
Applicability of Percutaneous Transluminal 
Coronary Angioplasty to Patients With 
Recombinant Tissue Plasminogen 
Activator Mediated Thrombolysis 
Eric J. Topol, MD, Jaan E. Eha, MD, Kenneth P. Brin, MD, 
Edward P. Shapiro, MD, James L. Weiss, MD, Mary B. Riegel, RN, 
Sidney 0. Gottlieb, MD, and Jeffrey A. Brinker, MD 
To test the utility and safety of percutaneous transluminal coronary angioplasty 
(PTCA) after recombinant tissue plasminogen activator (t-PA), we performed the 
procedure in all suitable candidates with acute myocardial infarction (MI) who had 
successful t-PA mediated coronary thrombolysis. Twenty consecutive patients with 
MI received t-PA after coronary angiographic conformation of total occlusion. Suc- 
cessful recanalization with 1-PA was achieved in 13 patients, leaving a residual 
obstruction of 84 f 6% in the nine patients for whom PTCA was attempted at a mean 
of 21.6 h. Success was achieved in seven patients, leading to a residual lesion of 29 
f 7%. In the two patients for whom PTCA was unsuccessful, total reocclusion 
occurred prior to the attempt despite therapy with heparin, aspirin, dipyridamole, 
and nifedipine. All PTCA procedures were uncomplicated. Serial two-dimensional 
echocardiography at 10 days, compared to admission, demonstrated infarct zone 
wall motion index improvement in the patients with successful PTCA (group A, 0.83 
f 0.36 to 1.46 f 0.49) as compared to the 13 patients without thrombolysis or 
successful PTCA (group B, 0.61 f 0.26 to 0.66 f 0.39), (P < 0.05). One patient of 
group A sustained a massive stroke at 2 weeks after hospital discharge. In the 
remaining six patients, follow-up exercise testing andlor coronary arteriography 
demonstrated a negative treadmill test andlor patent infarct vessel, respectively. 
After successful PTCA, no patient had clinical signs of reocclusion, reinfarction, 
postinfarction angina, or congestive heart failure. At 9.4 f. 2 months, all six patients 
are asymptomatic and have returned to work. Thus, sequential PTCA after t-PA can 
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be performed safely and successfully in patients with MI and this approach may be 
associated with improved regional function and a favorable post-MI course. 
Key words: coronary angioplasty, coronary thrombolysis, acute myocardial infarction, re- 
gional myocardial function 
INTRODUCTION 
Since the widespread acceptance of the high frequency and importance of total 
coronary artery occlusion in the early phase of acute myocardial infarction, various 
therapeutic strategies have been proposed. Recanalization of the infarct vessel with 
streptokinase, either by intracoronary or intravenous delivery, has been the most 
common method utilized to date [ 1-10]. However, several placebo controlled studies 
have not shown clear-cut benefit for patients in terms of recovery of left ventricular 
function [2,4,6,9]. With streptokinase administration, no matter which route is 
selected, there is attendant fibrinogenolysis and a prolonged lytic state [ 11-13]. With 
the introduction of human tissue-type plasminogen activator, produced by recombi- 
nant technology, an enzyme with a short half-life (< 5 min) [14,15] and relative 
fibrin selectivity has become available [ 16-23]. 
Besides thrombolytic therapy, percutaneous transluminal coronary angioplasty 
(PTCA), either directly or after streptokinase, has been performed in the setting of 
acute myocardial infarction and various studies point toward the potential advantage 
of this technique in promoting more complete and sustained infarct vessel recanaliza- 
tion [24-341. The current study was undertaken to determine the safety, feasibility, 
and outcome of combined therapy with t-PA and PTCA in patients with acute 
myocardial infarction. 
MATERIALS AND METHODS 
Patient Selection 
As part of a multicenter pilot trial of t-PA in acute myocardial infarction [18], 
patients who presented to either The Johns Hopkins Hospital or the Francis Scott Key 
Medical Center with chest pain of greater than 20 min but less than 6 h duration and 
associated with 2 1 mm of electrocardiographic ST segment elevation (in one or 
more leads) were considered for entry to the protocol. The exclusion criteria were 
cardiogenic shock, history of a bleeding diathesis, coronary artery bypass surgery or 
transmural myocardial infarction, age > 70 years, and significant hepatic, renal, and 
pulmonary disease. 
Angiography and Thrombolysis 
Once the above criteria were met, informed consent was obtained. The study 
protocol was approved by the institutional review boards of both hospitals. Patients 
underwent selective coronary arteriography, both of the infarct vessel and the nonin- 
farct related arteries, using the Judkins technique. After arterial access was obtained, 
heparin (100 U/kg, maximum 10,OOO U) was administered. Coronary angiograms 
were obtained in both right and left oblique projections as well as multiple hemiaxial 
views. Total occlusion of the infarct vessel was confirmed in 21 of 34 patients initially 
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entered into the study. According to the study design, only those patients with total 
occlusion were candidates for t-PA therapy.For the first 16 patients entered, there 
was two to one randomization between t-PA and placebo. In the placebo arm of the 
study, if no recanalization was observed after 30 min of serial angiography (angio- 
grams were performed every 15 min after the start of study drug to 2 hr), patients 
were crossed over to intracoronary t-PA (0.375 mg/kg over 15-30 min). Patients 
initially randomized to t-PA received this enzyme intravenously at dosages from 0.25 
to 0.75 mg/kg over 30-120 min. The last five patients who received t-PA in this study 
were treated on an open basis with 0.75 mg/kg over 120 min. Only one patient in the 
study achieved reperfusion during the placebo infusion, and no further data regarding 
this patient are presented here [18]. The remaining 20 consecutive patients who 
received t-PA, three by intracoronary delivery and 17 by intravenous administration, 
serve as the study group. Each patient who demonstrated reperfusion was placed an 
an antithrombotic regimen of heparin (1,OOO U/hr), aspirin (315 mg per day), 
dipyridamole (75 mg three times per day), and nifedipine (10 mg four times per day) 
immediately after the initial catheterization. 
Coronary Angioplasty 
All patients with suitable coronary artery anatomy were considered for coronary 
artery balloon dilatation. The criteria utilized to determine suitability were 1) success- 
ful t-PA mediated coronary thrombolysis; 2) a discrete, high grade residual stenosis 
at the site of prior occlusion; and 3) atherosclerotic disease confined to the infarct 
vessel or lack of critical, diffuse disease in the noninfarct related coronary arteries. 
Of 13 patients who exhibited recanalization after t-PA, four patients were not consid- 
ered candidates for PTCA. The reason for exclusion was severe, diffuse, multivessel 
disease in all four patients. Coronary angioplasty was performed in the remaining 
nine patients at a mean of 21.6 hr (range 0.5 hr to 3 days), the time dependent on 
cardiothoracic surgical backup availability. Angioplasty was performed via the fem- 
oral approach using USCI (Billerica, MA) guiding and dilatation catheters and guide 
wires. The balloon size was selected on the basis of estimated vessel size proximal to 
the target lesion. In the infarct vessel of each patient, the area of stenosis was dilated 
with 2-3 balloon inflations (range 4-11 atmospheres). Using caliper measurements, 
the residual lesion was quantitated as percent diameter stenosis averaging the value in 
two angiographic views, one in each obliquity. 
Evaluation of Regional Myocardial Function 
Regional left ventricular function was evaluated using serial two-dimensional echo- 
cardiography, performed prior to t-PA, throughout the infusion and for 1 hr after its 
completion, and at 1 and 10 days after admission. The echocardiograms were re- 
viewed by two observers, independently, and blinded to patient identity, the temporal 
sequence of study acquisition, therapy, and the effects of therapy. For analysis the 
myocardium was divided into seven segments, and the infarct zone was matched to 
the distribution of the infarct vessel, as determined by angiography. The infarct zone 
comprised a mean of 3.15 segments (range two to five segments) and each segment 
was scored using semiquantitative visual wall motion analysis. The grading utilized 
was - 1, dyskinesis, defined as paradoxical expansion of endocardial movement; 0, 
akinesis, or absence of endocardial motion; 1, hypokinesia, defined as reduced inward 
motion; and 2, normal. A wall motion score index for the infarct zone was calculated 
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according to a modification of the method of Heger et a1 [35] by averaging the scores 
for the two observers, summating the scores for the infarct zone segments, and 
dividing by the number of segments localized to this zone. This analysis was per- 
formed for the echocardiograms obtained prior to therapy and prehospital discharge, 
approximately 10 days after admission. 
Submaximal Exercise Treadmill Testing 
All patients who underwent PTCA attempts were exercised on a treadmill with 12- 
lead electrocardiographic monitoring prior to discharge. The target heart rate utilized 
was 120 beats/min and the test was stopped for symptoms of ischemia or electrocar- 
diographic 2 1 mm ST segment depression in one or more leads. In one patient who 
developed chest pain of uncertain etiology (atypical quality without accompanying 
electrocardiographic changes) and another patient who had equivocal ST segment 
changes during exercise, repeat coronary arteriography was performed. 
Postdischarge Follow-Up 
The status of each patient who underwent t-PA and PTCA therapy was determined 
by either direct out-patient examination or via telephone communication with the 
patient or his attending physician. 
Statistical Methods 
Unless otherwise stipulated, all values are reported as mean + 1 standard deviation 
of the mean. The infarct zone wall motion indices were compared for the patient 
groups using a paired t-test, and intergroup differences between admission and day 
10 index were tested using a one-way analysis of variance. 
RESULTS 
Recanalization 
Reperfusion of the infarct vessel was evident in 13 out of the 20 patients (65%) 
who received rt-PA. Relevant data are summarized in Table I .  This occurred at 5.1 
k 1.1 hr from the onset of chest pain, utilizing a dose of 43 17 mg of rt-PA. Of 
TABLE I. Patient and Therapy Characteristics' 
Age 55 f 5.7 years (range 39-69 years) 
Sex 17 male, three female 
Time (CP to lysis) 5.1 * 1.1 hr 
Time (CP to drug) 4.8 1.5 hr 
Site of occlusion LAD nine pts; LCx two pts; RCA nine 
PtS 
Dose of rt-PA 43 17 mg 
Route IV 17 pts, IC three pts 
Successful lysis 13 of 20 pts (65%); 12 of 17 pts (71 %)" 
*CP, chest pain; Drug, study medication; IC, intracoronary; IV, 
intravenous; LAD, left anterior descending coronary artery; LCx, left 
circumflex artery; lysis, coronary recanalization; pts, patients; rt-PA, 
recombinant tissue plasminogen activator. 
"Thrombolysis with intravenous recombinant tissue plasminogen 
activator. 
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those patients who received the enzyme intravenously (without the delay of a placebo 
infusion), 12 of 17 achieved thrombolysis. From the start of the infusion, the time to 
angiographic lysis was 36 f 9 min. The residual lesion after successful thrombolysis 
was 84 f 6%. The site of occlusion was the left anterior descending artery in nine 
patients, left circumflex artery in two patients, and the right coronary artery in nine 
patients. The infusion was not accompanied by any untoward effects in 16 patients; 
in four patients there was evidence of minor bleeding, from the gingiva in two 
patients, from the ear in one patient, and guaiac positive emesis in one patient. Six of 
the 20 patients had bleeding around the femoral vascular access sites either while the 
sheaths were in place or in small, localized hematomas after the sheaths were 
removed. No patient received a blood transfusion during the course of the study. 
Coronary Angioplasty 
PTCA was attempted in nine patients (Table 11). In two patients reocclusion of the 
infarct vessel was noted at the time of angioplasty attempt. Both of these patients had 
been asymptomatic between the time of successful thrombolysis and repeat control 
angiography for coronary dilatation. Despite multiple attempts to cross the site of 
total occlusion, a guide wire could not be advanced in one patient and a 2.0 mm low 
profile dilating catheter could not successfully traverse the other patient’s occlusion. 
In the other seven patients, PTCA was successful. A representative set of angiograms 
is shown in Figure 1. The residual stenosis was reduced from 84 f 6% to 29 f 7 % . 
The residual transstenotic gradient was less than 15 mm Hg in all of these patients. 
No complication of the procedure occurred in any of the patients for whom the 
procedure was attempted. There was angiographic evidence of localized intimal 
dissection in four of the seven patients. 
Hospital Course: Clinical Outcome 
Of the patients reperfused, the seven who had successful coronary angioplasty had 
no evidence of reinfarction, postinfarction angina, congestive heart failure, or reoc- 
clusion or need for coronary artery bypass surgery. In the six patients who exhibited 
recanalization but did not undergo angioplasty (or this procedure was unsuccessful), 
there was evidence of reocclusion in four patients, reinfarction in one patient, 
postinfarction angina in three patients, and coronary artery bypass surgery was 
performed in three patients. 
Response to Exercise Testing 
Of the patients who had successful rt-PA mediated coronary thrombolysis and 
PTCA, five of seven had a negative submaximal graded exercise treadmill test. In 
two of these patients repeat coronary arteriography was performed because of either 
an equivocal exercise electrocardiogram or atypical chest pain, and both patients 
demonstrated a widely patent infarct vessel. 
Regional Myocardial Function 
In the seven patients reperfused and mechanically revascularized, the infarct zone 
wall motion index significantly improved (from 0.83 f 0.36 on admission to 1.46 f 
0.49 at 10 days; P = 0.01) compared to those patients with successful thrombolysis 
only (from 0.58 f 0.25 to 0.80 L- 0.33 at 10 days, P = NS) or those patients without 
recanalization (from 0.63 0.32 to 0.54 f 0.42 at 10 days, P = NS). The differ- 
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Fig. 1. Serial cineangiograms of the left anterior descending coronary artery from a study 
patient. A) Left anterior oblique projection shows total occlusion (arrow). B) Midway through 
the t-PA infusion recanalization is apparent with slow and incomplete filling of the distal vessel 
(arrow) and residual thrombus at the site of previous occlusion. C) Thirty minutes after 
completion of the infusion, a high grade residual lesion is evident (arrow). D) Just prior to 
angioplasty (40 h postinfarct) a persistent high grade stenosis (arrow) is apparent. E) After 
coronary angiography, a minimal residual lesion is shown with haziness at the site of dilatation 
(arrow). 
ences in baseline infarct zone wall motion indices were not statistically significant 
(ANOVA). Further, there was significant improvement in the infarct zone index of 
the patient group with successful thrombolysis and PTCA compared to the other two 
groups (F = 5.85, P < 0.05, one way ANOVA; Fig. 2). 
Follow-Up 
One patient who had successful thrombolysis and PTCA sustained a massive stroke 
2 weeks after hospital discharge. The remaining six patients in this group have 
returned to work and are asymptomatic at 9.4 f 2 months. One patient became 
symptomatic with angina 7 months after hospital discharge. Coronary arteriography 
demonstrated restenosis (90%) of the right coronary artery lesion and this was 
successfully dilated. Repeat graded exercise testing was negative and the patient is 
free of symptoms. 
DISCUSSION 
Our results demonstrate that coronary angioplasty can be performed safely and 
succesfully after tissue plasminogen activator thrombolytic therapy in patients with 
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Fig. 2. Regional myocardial function on admission and at 10 days after therapy with either 
reperfusion with t-PA and sequential PTCA, thrombolysis only or no reperfusion. The infarct 
zone wall motion index (mean f SD) is plotted versus the time of the study for each patient 
group. There was significant improvement of infarct zone segmental motion only in the patient 
group with successful t-PA mediated thrombolysis and mechanical revascularization. 
acute myocardial infarction. Although this represents a small, uncontrolled series, 
this combined interventional strategy was correlated with a favorable in-hospital and 
long-term clinical outcome as well as clear-cut improvement in regional wall motion 
of the infarct zone. 
Rationale for Combination Therapy 
The vast majority of patients with acute coronary occlusion who achieve reperfusion 
after thrombolytic therapy are left with a high grade stenotic lesion [36-381. The 
atherosclerotic plaque narrowing has important potential consequences. First, it ap- 
pears to serve as a nidus for rethrombosis, and the incidence of reocclusion is 
inversely correlated to the artery cross-sectional area after recanalization [37]. The 
propensity to reocclude may relate to the adherence of fibrin to the atherosclerotic 
plaque, as we have previously demonstrated to occur in an experimental atheroscler- 
otic model after therapy with t-PA [39]. The propagation of a thrombus may thus be 
enhanced under conditions of reduced flow. Second, the high grade atherosclerotic 
lesion is usually flow-limiting , so that myocardial tissue is still “underperfused” and 
evaluation of function may be confounded because it is difficult to distinguish accu- 
rately infarcted versus ischemic myocardium. In this setting, the effects of coronary 
angioplasty may be particularly complementary and desirable by virtue of their 
potential to reduce the propensity for rethrombosis and provide more complete 
revascularization to the infarct zone. 
Comparison With Previous Studies 
There are several prior studies of patients with myocardial infarction that confirm 
the ability of PTCA to achieve a high primary success rate either after thrombolytic 
therapy or directly [24-341. Most of these investigations support a diminished inci- 
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TABLE II. Response to Therapy With rt-PA and PTCA' 
Patient Time to Time to Dose Residual lesion 
No. Age Sex Vessel lysis (hr)a PTCA (hr) t-PA (mg) Route after lysis (%) 
1 69 M LAD 4.1 12 25 IC 97.5 
2 40 M RCA 5.5 0.6 40 IV 82.6 
3 54 F RCA 5.8 40 62 IV 86.9 
4 56 M RCA 4.2 62 40 IV 81.7 
5 68 F RCA 6.4 38 38 IV '81.4 
6 68 F LAD 6.1 40 17 IV 76.2 
7 68 M RCA 4.6 1 94 IV 85.7 
8 39 M LAD 6.2 1 30 IV 88.1 
9 53 M LAD 3.1 0.75 62 IV 95 
Total 57.2 6 M ,  4LAD,  5.1 5 1.1 2 1 . 6 i 2 3  45 i 2 3  I I C ,  8 3 . 9 i 5 . 7  
*ETT, exercise treadmill test predischarge; IV, intravenous; IC, intracoronary; lysis, coronary 
recanalization; LAD, left anterior descending coronary artery; RCA, right coronary artery; PTCA, 
percutaneous transluminal coronary angioplasty ; rt-PA, recombinant tissue plasminogen activator. 
aTime from onset of chest pain. 
unsuccessful. 
3 F  5RCA 8 IV 
two patients, control angiography at PTCA attempt revealed total reocclusion and the procedure was 
dence of reocclusion when the two interventions, streptoly sis and angioplasty, are 
combined compared to only thrombolysis. However, only two such studies were 
randomized [28,34] and the endpoint for all has been angiographic appearance of the 
vessel either acutely or prehospital discharge. In a recent study, Yasuno et a1 [33] 
considered global and regional ventricular function after urokinase and PTCA and 
demonstrated improvement at 6 weeks postinfarct. And, in a randomized study by 
O'Neill et a1 [34], direct coronary angioplasty was superior to intracoronary strepto- 
kinase in leading to improved myocardial blood flow and left ventricular function. 
Prior studies of sequential thrombolysis and angioplasty therapy are summarized in 
Table 111. 
Advantages of Thrombolysis With t-PA 
The key theoretical advantages of t-PA compared to first-generation lytic agents, 
streptokinase and urolunase, relate to its fibrin selectivity, short half-life, and lack of 
antigenicity. Via the intravenous route, the ability of rt-PA to dissolve coronary 
thrombus has been approximately 75% [18], which compares favorably to the 50- 
55% efficacy rate of intravenous streptokinase [8,40], and this increased rate of 
thrombolysis has been associated with a relative sparing of fibrinogen and absence of 
a systemic lytic state [14,18]. However, it has become clear that too high a dose of t -  
PA may lead to similar effects as those of streptokinase by virtue of the production of 
free plasmin [41-431. The short half-life of this enzyme offers particular advantage 
for sequential, surgical or transluminal balloon coronary revascularization, since these 
procedures can be accomplished without the hazard of prolonged or severe bleeding. 
On the other hand, the short time span of fibrinolysis with t-PA may allow more acute 
rethrombosis in comparison with intravenous streptokinase, which at the doses cur- 
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TABLE II (Continued) 
Residual lesion Localized Infarct wall motion index 
after PTCA (%) dissection Admission Day 10 ETT FOIIOW-UP 
b - No 0.5 0.66 Not done Successful CABG 
35 Yes 1.12 1.4 Negative Asymptomatic 
27.8 Yes 1.25 1.87 Negative Asymptomatic 
36.2 No 0.33 0.83 Atypical Repeat angiography- 
- No 0.67 1.33 Negative Asymptomatic 
19.3 No 0.83 2.0 Negative Asymptomatic 
25 No 0.37 1.75 Negative Restenosis at 9 months; 
23.6 Yes 0.82 1.66 Equivocal Repeat angiography- 
chest pain patency, asymptomatic 
b 
successful repeat PTCA 
patency; stroke 2 weeks 
after discharge 
37.2 Yes 1.12 0.75 Negative Asymptomatic 
29.2 k 7.0 4 yes, 0.77 k 0.33 1.36 0.50 
5 no 
rently utilized (750,000 to 1.5 million units) leads to at least a 24-hr period of a 
systemic lytic state. 
Timing of Coronary Angioplasty 
In the present study, PTCA was performed either directly following thrombolysis 
or after transfer of the patient and/or surgical backup could be provided. It is unclear 
what represents the optimal timing for PTCA after coronary thrombolysis, assuming 
that these interventions are done sequentially. In most previous studies, coronary 
angioplasty was performed immediately after recanalization was established with lytic 
therapy. But this strategy is not readily transferable to a community hospital that is 
not set up for coronary angioplasty but has the necessary personnel to administer 
readily a safe fibrinolytic agent. Several experimental and clinical studies point toward 
the critical importance of time to the salvage of myocardium [44-461. The regional 
wall motion improvement observed in our study did not appear to relate to the time 
of angioplasty, but clearly this series is too small to make any conclusion. If such a 
benefit can be confirmed in large, controlled trials, sequential therapy of fibrinolytic 
and mechanical therapy could be widely applied. 
Limitations 
In view of the small number of patients in this pilot study, our results must be 
considered preliminary and will require confirmation and replication in larger, con- 
trolled trials that are currently underway. Coronary angioplasty was not performed 
on a randomized basis. The selection criteria for this procedure were successful 
reperfusion and suitable coronary artery anatomy. Although coronary dilatation was 
associated with significant regional wall motion improvement, this may have been 
due to the favorable anatomy itself, which may correlate with subsequent functional 
recovery. Our results indicate that reperfused, infarct zone segments without subse- 
quent PTCA lacked significant wall motion improvement compared to infarct regions 
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TABLE 111. Prior Studies of Coronarv Thrombolvsis and PTCA’ 
No. Lytic Time of Success Late patency 
Reference patients agent PTCA (hr) (%) (%) 
Meyer et a1 [24] 21 SK 1 81 Not studied 
Gold et a1 [25] 28 SK Immediate 71 55 (8-14 days) 
Hartzler et al [27] 39 SK Immediate 87 94 (10 days); 
Uebis et a1 [28] 25 SK Immediate 96 100 (3 days) 
Papapietro et a1 [29] 18 SK Immediate 72 69 (8-17 days) 
Kalbfleisch et a1 [30] 15 SK Immediate 93 1 0 0  (6 weeks) 
Holmes et a1 1311 22 SK Immediate 68 Not studied 
Schwarz et a1 [32] 28 SK Immediate 89 Not studied 
Yasuno et a1 [33] 32 UK Immediate 72 66 (42 days) 
Pooled results 228 8SK,  1 UK 81 75 (3-42 days) 
*SK, streptokinase; UK, urokinase; late patency, widely patent vessel at repeat angiography ; time of 
PTCA, time after coronary thrombolytic therapy. 
79 (6 months) 
not reperfused. Thus, it remains possible that coronary artery dilatation was the sole 
factor responsible for improvement. 
Implications 
The exact role of coronary angioplasty in acute myocardial infarction remains 
unclear but there are numerous advantages that have already been observed. It appears 
technically preferable to administer a fibrinolytic agent immediately, allowing for the 
time to set up an invasive cardiology laboratory for coronary angioplasty . Recanali- 
zation of the infarct vessel would at least provide a “roadmap” for the dilatation 
hardware and potentially make the angioplasty procedure safer and easier. Perhaps 
more important, however, is the prompt restoration of flow, albeit often incomplete, 
with a chemical means of therapy. The time required to administer an intracoronary 
agent has been at least 1.5 to 2 hr [l-8,101 from patient identification into a study 
protocol and would be expected to be at least this long for a PTCA procedure; the 
optimal timing of this procedure remains undefined. In the interval period of time, 
thrombolysis could be achieved. Tissue plasminogen activator has several properties 
that combined with coronary angioplasty may make this sequence of interventions the 
optimal therapy for patients with acute myocardial infarction. 
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